Literature DB >> 27107173

Front-to-back & dabbing wiping behaviour post-toilet associated with anal neoplasia & HR-HPV carriage in women with previous HPV-mediated gynaecological neoplasia.

Steve Simpson1, Penny Blomfield2, Alyssa Cornall3, Sepehr N Tabrizi4, Leigh Blizzard5, Richard Turner6.   

Abstract

BACKGROUND: Anal cancer is a human papillomavirus (HPV)-mediated neoplasia of the anal squamous epithelium. Anal cancer is much more common among women, particularly those with a previous high-grade gynaecological neoplasia.
METHODS: Cross-sectional study of women with a previous HPV-mediated gynaecological neoplasia in Tasmania, Australia. Women presenting for follow-up gynaecological care had anal swab samples taken for anal cytology by Hologic Liquid ThinPrep, followed by HPV genotyping. Women with abnormal anal cytology were invited for high-resolution anoscopy. Potential risk factors, including post-toilet wiping behaviours, were queried by questionnaire while clinical covariates were extracted from medical records. Covariates of anal outcomes evaluated by log-binomial and log-multinomial regression.
RESULTS: From 163 women enrolled in the study, 65 (39.9%) had abnormal cytology, with 46 (28.2%) being high-grade. Of the 50 women with abnormal anal cytology having high-resolution anoscopy, 32 (64.0%) had abnormal histology with 13 (26.0%) being high-grade. Of the 123 women tested for HR-HPV DNA, 48 (39.0%) had HR-HPV detected, the most common genotypes being 16 and 51 (14/123, 11.4% for both). In addition to some known anal cancer risk factors, we found front-to-back wiping was associated with significantly increased (Prevalence ratio (PR) range: 1.99-3.60) prevalence of cytological and histological abnormality and HR-HPV carriage/co-carriage, while dabbing post-toilet was significantly associated with decreased prevalences (PR range: 0.50-0.62).
CONCLUSIONS: Post-toilet wiping behaviours were significantly associated with the prevalence of anal cytological, histological and HR-HPV carriage outcomes. This suggests a biologically plausible mechanism for HR-HPV introduction and the higher frequencies of anal neoplasia in women.
Copyright © 2016. Published by Elsevier Ltd.

Entities:  

Keywords:  Anal neoplasia; Epidemiology; Human papillomavirus; Perineal hygiene; Post-toilet wiping; Women

Mesh:

Year:  2016        PMID: 27107173     DOI: 10.1016/j.canep.2016.04.001

Source DB:  PubMed          Journal:  Cancer Epidemiol        ISSN: 1877-7821            Impact factor:   2.984


  9 in total

1.  Prevalence of and Risk Factors for Anal High-grade Squamous Intraepithelial Lesions in Women Living with Human Immunodeficiency Virus.

Authors:  Elizabeth A Stier; Shelly Y Lensing; Teresa M Darragh; Ashish A Deshmukh; Mark H Einstein; Joel M Palefsky; Naomi Jay; J Michael Berry-Lawhorn; Timothy Wilkin; Dorothy J Wiley; Luis F Barroso; Ross D Cranston; Rebecca Levine; Humberto M Guiot; Audrey L French; Deborah Citron; M Katayoon Rezaei; Stephen E Goldstone; Elizabeth Chiao
Journal:  Clin Infect Dis       Date:  2020-04-10       Impact factor: 9.079

2.  Anal Cancer and Anal Cancer precursors in Women with a History of HPV-Related Dysplasia and Cancer.

Authors:  Elizabeth A Stier; Elizabeth Y Chiao
Journal:  Semin Colon Rectal Surg       Date:  2017-04-26

3.  Cervical determinants of anal HPV infection and high-grade anal lesions in women: a collaborative pooled analysis.

Authors:  Chunqing Lin; Jiri Slama; Paula Gonzalez; Marc T Goodman; Ningshao Xia; Aimée R Kreimer; Ting Wu; Nancy A Hessol; Yurii Shvetsov; Ana P Ortiz; Beatriz Grinsztejn; Anna-Barbara Moscicki; Isabelle Heard; María Del Refugio González Losa; Erna M Kojic; Maarten F Schim van der Loeff; Feixue Wei; Adhemar Longatto-Filho; Zizipho A Mbulawa; Joel M Palefsky; Annette H Sohn; Brenda Y Hernandez; Katina Robison; Steve Simpson; Lois J Conley; Alexandra de Pokomandy; Marianne A B van der Sande; Racheal S Dube Mandishora; Lays P B Volpini; Alessandra Pierangeli; Byron Romero; Timothy Wilkin; Silvia Franceschi; Carmen Hidalgo-Tenorio; Reshmie A Ramautarsing; Ina U Park; Fernanda K Tso; Sheela Godbole; Kathleen W M D'Hauwers; Borek Sehnal; Lynette J Menezes; Sandra A Heráclio; Gary M Clifford
Journal:  Lancet Infect Dis       Date:  2019-06-13       Impact factor: 25.071

4.  Anal human papillomavirus infection in HIV-positive men and women at two opportunistic infections clinics in Harare, Zimbabwe.

Authors:  Simbarashe Chinyowa; Joel M Palefsky; Zvavahera M Chirenje; Rudo Makunike-Mutasa; Marshall Munjoma; Godfrey I Muguti
Journal:  BMC Public Health       Date:  2018-11-14       Impact factor: 3.295

5.  Opportunistic detection of anal intraepithelial neoplasia at colonoscopy.

Authors:  Clara M Forbes; Jenny McCloskey; Geoffrey M Forbes
Journal:  JGH Open       Date:  2020-10-14

6.  Sequential Acquisition of Human Papillomavirus Infection at Genital and Anal Sites, Liuzhou, China.

Authors:  Feixue Wei; Yingying Su; Xuelian Cui; Xiaojuan Yu; Yafei Li; Qiaoqiao Song; Kai Yin; Shoujie Huang; Mingqiang Li; Jun Zhang; Ting Wu; Ningshao Xia
Journal:  Emerg Infect Dis       Date:  2020-10       Impact factor: 6.883

7.  High Prevalence of Rectal Chlamydia trachomatis Infection With the Same Genotype as Urogenital Infection in Female Outpatients in Sexually Transmitted Disease Clinics in China.

Authors:  Yan Han; Kai Chen; Jing-Wei Liu; Bang-Yong Zhu; Ke Zhou; Mei-Qin Shi; Wen-Qi Xu; Tulip A Jhaveri; Yue-Ping Yin; Xiang-Sheng Chen
Journal:  Open Forum Infect Dis       Date:  2021-11-19       Impact factor: 3.835

8.  Anal cancer in high-income countries: Increasing burden of disease.

Authors:  Yoon-Jung Kang; Megan Smith; Karen Canfell
Journal:  PLoS One       Date:  2018-10-19       Impact factor: 3.240

9.  Rectal Mycoplasma genitalium in Patients Attending Sexually Transmitted Disease Clinics in China: An Infection That Cannot Be Ignored.

Authors:  Yan Han; Yue-Ping Yin; Jing-Wei Liu; Kai Chen; Bang-Yong Zhu; Ke Zhou; Mei-Qin Shi; Wen-Qi Xu; Tulip A Jhaveri; Xiang-Sheng Chen
Journal:  Infect Drug Resist       Date:  2021-06-30       Impact factor: 4.003

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.